The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Open accessAbstract
We explored the utility of targeting anaplastic lymphoma kinase (ALK), a cell surface receptor overexpressed on pediatric solid tumors, using chimeric antigen receptor (CAR)-based immunotherapy. T cells expressing a CAR incorporating the single-chain variable fragment sequence of the ALK48 mAb linked to a 4-1BB-CD3ζ signaling domain lysed ALK-expressing tumor lines and produced interferon-gamma upon antigen stimulation but had limited anti-tumor efficacy in two xenograft models of human neuroblastoma. Further exploration demonstrated that cytokine production was highly dependent upon ALK target density and that target density of ALK on neuroblastoma cell lines was insufficient for maximal activation of CAR T cells. In addition, ALK CAR T cells demonstrated rapid and complete antigen-induced loss of receptor from the T cell surface via internalization. Using a model that simultaneously modulated antigen density and CAR expression, we demonstrated that CAR functionality is regulated by target antigen and CAR density and that low expression of either contributes to limited anti-tumor efficacy of the ALK CAR. These data suggest that stoichiometric relationships between CAR receptors and target antigens may significantly impact the anti-tumor efficacy of CAR T cells and that manipulation of these parameters could allow precise tuning of CAR T cell activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Self-citationIdentification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
T-cell-antigen recognition and the immunological synapse
Huppa, J. B., & Davis, M. M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1245 · Cited by 643
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Self-citationLiu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
The biology and treatment of EML4-ALK non-small cell lung cancer
Sasaki, T., Rodig, S. J., Chirieac, L. R., & Jänne, P. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.002 · Cited by 555
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
Huang, J., Brameshuber, M., Zeng, X., Xie, J., Li, Q.-J., Chien, Y.-H., Valitutti, S., & Davis, M. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.036 · Cited by 385
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
Self-citationZhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Self-citationWatanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., Till, B. G., Raubitschek, A. A., Forman, S. J., & Press, O. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7028 · Cited by 249
Faroudi, M., Utzny, C., Salio, M., Cerundolo, V., Guiraud, M., Müller, S., & Valitutti, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2334336100 · Cited by 239
Itoh, Y., & Germain, R. N. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.757 · Cited by 213
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 181
Passoni, L., Longo, L., Collini, P., Coluccia, A. M. L., Bozzi, F., Podda, M., Gregorio, A., Gambini, C., Garaventa, A., Pistoia, V., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4419 · Cited by 173
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S. M., Prince, H. M., Ritchie, D. S., Trapani, J. A., Kershaw, M. H., Darcy, P. K., & Neeson, P. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0048 · Cited by 164
A sharp T-cell antigen receptor signaling threshold for T-cell proliferation
Au‐Yeung, B. B., Zikherman, J., Mueller, J. L., Ashouri, J. F., Matloubian, M., Cheng, D. A., Chen, Y., Shokat, K. M., & Weiss, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413726111 · Cited by 161
Moog-Lutz, C., Degoutin, J., Gouzi, J. Y., Frobert, Y., Carvalho, N. B.-D., Bureau, J., Créminon, C., & Vigny, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501972200 · Cited by 158
Self-citationJena, B., Maiti, S. N., Huls, H. M., Singh, H., Lee, D. A., Champlin, R. E., & Cooper, L. J. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057838 · Cited by 138
Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
Anurathapan, U., Chan, R. C., Hindi, H. F., Mucharla, R., Bajgain, P., Hayes, B. C., Fisher, W. E., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.262 · Cited by 128
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Almåsbak, H., Walseng, E., Kristian, A., Myhre, M. R., Inderberg, E. M., Munthe, L. A., Andersen, J. T., WANG, M. Y., Kvalheim, G., Gaudernack, G., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.4 · Cited by 117
Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
Orentas, R. J., Yang, J. J., Wen, X., Wei, J. S., Mackall, C. L., & Khan, J. I. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00194 · Cited by 113
Self-citationSchulte, J. H., Bachmann, H. S., Brockmeyer, B., Preter, K. D., Oberthür, A., Ackermann, S., Kahlert, Y., Pajtler, K. W., Theißen, J., Westermann, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2809 · Cited by 107
Shimizu, R., Kikuchi, J., Wada, T., OZAWA, K., Kano, Y., & Furukawa, Y. (2010) · Leukemia · doi:10.1038/leu.2010.157 · Cited by 106
Weijtens, M. E. M., Hart, E., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301051 · Cited by 95
Kettleborough, C. A., Saldanha, J. W., Ansell, K. H., & Bendig, M. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230132 · Cited by 94
Song, D.-G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4071 · Cited by 94
Rachmilewitz, J., & Lanzavecchia, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02342-6 · Cited by 88
Hombach, A. A., Görgens, A., Chmielewski, M. M., Murke, F., Kimpel, J., Giebel, B., & Abken, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.82 · Cited by 82
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
Mossé, Y. P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1100 · Cited by 77
Turatti, F., Figini, M., Balladore, E., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de5d90 · Cited by 77
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Carpenter, E. L., Haglund, E. A., Mace, E. M., Deng, D., Martínez, D., Wood, A., Chow, A. K., Weiser, D. A., Belcastro, L. T., Winter, C. L., et al. (2012) · Oncogene · doi:10.1038/onc.2011.647 · Cited by 73
Hooijberg, E., Bakker, A. Q., Ruizendaal, J. J., & Spits, H. (2000) · Blood · doi:10.1182/blood.v96.2.459 · Cited by 65
Hoffmann, D., Schott, J. W., Geis, F. K., Lange, L., Müller, F.-J., Lenz, D., Zychlinski, D., Steinemann, D., Morgan, M. A., Moritz, T., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.20 · Cited by 61
Regulation of Vesicular Traffic at the T Cell Immune Synapse: Lessons from the Primary Cilium
Finetti, F., Onnis, A., & Baldari, C. T. (2014) · Traffic · doi:10.1111/tra.12241 · Cited by 38
James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., Budde, L. E., Till, B. G., Raubitschek, A. A., Forman, S. J., & Press, O. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903701 · Cited by 30
Ciardiello, C., Roca, M. S., Noto, A., Bruzzese, F., Moccia, T., Vitagliano, C., Gennaro, E. D., Ciliberto, G., Roscilli, G., Aurisicchio, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7195 · Cited by 27
Álvarez‐Vallina, L., & Russell, S. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950018634 · Cited by 25
On the Mechanism of T cell receptor downmodulation and its physiological significance
Escors, D. (2011) · The Journal of Bioscience and Medicine · doi:10.5780/jbm2011.5 · Cited by 19
Cited by
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Self-citationTumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Self-citationMechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Self-citationc-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891
Self-citationRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Metadata
- Authors
- Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., & Mackall, C. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 25
- Issue
- 9
- Pages
- 2189-2201
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2624700430
- Cited by
- 383
- References
- 60
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.